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PENCIRIAN ANTIBODI REKOMBINAN YANG MENSASARKAN 
PROTEIN KAPSID HIV-1 (P24): KE ARAH PEMBANGUNAN ANTIBODI 
TERAPEUTIK TERHADAP HIV/AIDS 
 
 
ABSTRAK 
 
Virus imunodifisiensi manusia (HIV) adalah agen penyebab sindrom kurang 
daya tahan terhadap penyakit (AIDS). Peningkatan morbiditi dan kematian akibat 
HIV/AIDS dalam beberapa dekad kebelakangan ini telah mencetuskan perhatian untuk 
memerangi penyakit berkenaan. Walau bagaimanapun, penyelidikan yang dijalankan 
secara berterusan didapati masih gagal untuk membasmi jangkitan HIV/AIDS. 
Pengenalan terhadap terapi anti-retroviral yang sangat aktif (HAART) pada awal 
tahun 1990 telah mengurangkan kadar kematian HIV/AIDS, namun ia mewujudkan 
strain HIV yang mempunyai rintangan terhadap dadah/ ubat-ubatan. Oleh itu, terdapat 
keperluan yang mendesak untuk membangunkan kaedah terapeutik baharu yang lebih 
baik. HIV-1 kapsid protein (p24) memainkan peranan penting dalam kedua-dua 
peringkat replikasi awal dan lewat virus HIV-1. Molekul kecil Inhibitor dan peptida 
yang mensasarkan p24 membuktikan jangkitan virus berkenaan dapat dihalang. Walau 
bagaimanapun, faktor perembesan pantas dan ketoksikan molekul/peptide tersebut 
merupakan kelemahan utama yang berkaitan dengan kaedah terapeutik di atas. Potensi 
antibodi monoklon (mAbs) yang berupaya mensasarkan p24 telah diterokai. Antibodi 
monoklon berkenaan dapat dibangunkan sebagai modaliti terapeutik yang baharu. 
Walau bagaimanapun, antibodi monoklon semula jadi atau yang diperoleh dari 
hybridoma merupakan molekul bersaiz besar yang sukar untuk menembusi sel. 
Teknologi DNA rekombinan membolehkan kejuruteraan antibodi dibangunkan dalam 
pelbagai format. Oleh itu, matlamat kajian ini adalah untuk menjana, mencirikan, dan 
xviii 
 
menilai antibodi rekombinan yang mensasarkan HIV-1 p24. Antibodi rekombinan 
anti-p24 dijana dari kombinasi pelbagai kumpulan domain yang diklon daripada sel 
hybridoma dan seterusnya dihasilkan pada permukaan filamen bakteriofaj. ScFvs 
rekombinan yang bertindak secara spesifik terhadap p24 HIV-1 telah diperoleh dan 
dikenal pasti. Daripada 50 klon, tiga scFvs yang spesifik telah dikenal pasti melalui 
ujian ELISA. scFvs tersebut telah disahkan melalui competitive ELISA dan klon-klon 
berkenaan kemudiannya dihasilkan di dalam E. coli. ScFvs rekombinan didapati 
berupaya menghalang pempolimeran p24 secara in vitro dan replikasi HIV di dalam 
beberapa jujukan Jurkat T sel apabila dihasilkan sebagai antibodi intrasel 
(intrabodies). ScFvs anti-p24 yang dihasilkan daripada kajian ini mempunyai potensi 
untuk dibangunkan sebagai kaedah terapeutik baharu yang berasaskan antibodi 
terhadap HIV. 
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CHARACTERIZATION OF RECOMBINANT ANTIBODIES TARGETING 
HIV-1 CAPSID PROTEIN (P24): TOWARDS THE DEVELOPMENT OF 
ANTIBODY-BASED THERAPY AGAINST HIV/AIDS 
 
 
ABSTRACT 
 
Human immunodeficiency virus (HIV) is the causative agent of acquired 
immune deficiency syndrome (AIDS) disease. Increasing morbidity and mortality due 
to HIV/AIDS in decades has sparked an interest to combat HIV/AIDS. However, 
ongoing research against the HIV/AIDS pandemic has failed to completely eradicate 
the infection. Introduction of highly active anti-retroviral therapy (HAART) in early 
1990s has reduced the death rate of HIV/AIDS, but it has also resulted in the 
development of drug-resistant strains of HIV. Therefore, there is a pressing need to 
develop new and improved therapeutic modalities. HIV-1 capsid protein (p24) plays 
important roles in both early and late stages of HIV-1 replication. Small molecule 
inhibitors and peptides targeting p24 have shown to inhibit viral infection. However, 
rapid clearance and toxicity are major drawbacks associated with the above-mentioned 
therapeutic modalities. The potential of monoclonal antibodies (mAbs) targeting p24 
was discovered and found out that p24-targeting antibodies can be developed into 
novel therapeutic modalities. However, natural or hybridoma-derived mAbs are large 
molecules and difficult to engineer. Recombinant DNA technology allows the 
engineering of antibodies in multiple formats. Therefore, the aim of this study was to 
generate, characterize, and evaluate recombinant antibodies targeting HIV-1 
p24. Recombinant anti-p24 antibodies were generated from a combinatorial library of 
variable domains cloned from a hybridoma cell line and subsequently expressed on the 
surface of filamentous bacteriophage. Recombinant scFvs reacting specifically with 
xx 
 
HIV-1 p24 were isolated, expressed, and characterized. Out of 50 clones, three specific 
binders were identified via initial ELISA screening. Specificity of the binders was 
confirmed through competition studies and the selected clones were expressed in E. 
coli. The recombinant scFvs markedly inhibited p24 polymerization in vitro and HIV 
replication in Jurkat T cell lines when expressed as intracellular antibodies 
(intrabodies). The anti-p24 scFvs engineered in this study have potential to be 
developed into novel antibody–based therapeutics against HIV. 
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CHAPTER 1: INTRODUCTION 
1.1. Background of the study 
1.1.1. HIV and AIDS 
Human immunodeficiency virus (HIV) is categorized into two types: HIV-1 and HIV-
2. The routes of transmission for both types are similar and are causative agents for 
acquired immunodeficiency disease syndrome (AIDS). HIV-1 is more pathogenic as 
compared to HIV-2 thus making it the more predominant virus. There are three HIV-
1 groups which composed of M, N, and O groups. Among these groups, M is the main 
group that covers 90% of the HIV-1 infection. Recently, a new group was identified 
known as group P. Within group M, there are nine subtypes with 15-20% genetic 
variations (A, B, C, D, F, G, H, J, and K) in which Subtype C was identified as the 
cause of 50% of the total HIV-1 infections in 2004 (Kurth & Bannert, 2010).  
HIV is transmitted by several ways; predominantly from sexual intercourse, from 
mother to child, intravenous drug injection or contaminated blood transfusion. In 
Malaysia, until 2015, the number of people living with HIV was 92,895 or almost 0.5% 
of the entire population (MOH reports). This number has increased from 91,362 cases 
of HIV infections at the end of 2010. Choy (2014) reported that the development of 
highly active antiretroviral therapy (HAART) in the 1990s had reduced or slowed 
down the death rate of the HIV/AIDS patients in Malaysia. The most-at-risk-
populations for HIV transmission in Malaysia are, injecting drug users (IDUs), 
transgender people, sex workers, and migrant workers (Choy, 2014).  
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1.1.2. HIV Pathogenesis 
The HIV-1 genome is approximately 9.8 kb in length that encode for structural, 
regulatory, and accessory proteins which flanked by repeated sequence known as long 
terminal repeats (LTRs) (Figure 1.1.1). By having these proteins, HIV-1 is considered 
a complex retrovirus. HIV-1 LTRs are composed of promoter and enhancer sequences 
as well as polyadenylation site. They are important for reverse transcription, 
integration and gene expression steps. The HIV genome contains nine genes. In 
addition to the gag, pol, and env genes coding for structural proteins (Matrix, Capsid, 
Nucleocapsid, p6) and enzymes (protease, reverse transcriptase, integrase), there are 
two regulatory (tat and rev) and four accessory genes (vif, vpr, vpu, and nef) which are 
present in the HIV as a complex retrovirus (Li et al., 2015).   
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Figure 1.1.1. HIV-1 genome. HIV-1 genome consists of structural, regulatory and 
accessory genes flanked by the promoters in LTRs (Suzuki & Suzuki, 2011). 
MA (matrix), CA (capsid), NC (nucleocapsid), PR (protease), RT(reverse 
transcriptase), IN (integrase), SU (gp120), TM (gp41). 
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Pathogenesis of the virus is attributed to the direct and indirect mechanism of all the 
viral genes. They are involved differently at each step of the viral replication – from 
the early stage until the release of the virus from the host cell (Figure 1.1.2). Firstly, 
the viral gp120 will recognize the host cell surface receptor, CD4. The glycoprotein 
undergoes conformational changes that allows binding to the co-receptor (either CCR5 
or CXCR4, depending on the HIV tropism). This is followed by fusion with the cell 
membrane which is mediated by the transmembrane gp41 protein. The viral capsid is 
subsequently released into the cytoplasm. Once in the cell, the viral capsid is partially 
disassembled and reverse transcription takes place. This process is facilitated by the 
reverse transcriptase enzyme to form viral DNA. Viral DNA, p17 Gag, integrase, and 
Vpr are contained in the preintegration complex (PIC). The viral DNA is transported 
to the nucleus and with the assistance of integrase and Vpr protein, the DNA integrates 
with the host DNA to produce a provirus (Fauci, 2007).  
In the nucleus, the provirus DNA is transcribed by the host RNA polymerase into 
RNA. This process is mediated by Tat that binds at the LTR sequence to promote 
transcription of longer copies of the viral genome. RNA splicing takes place either 
singly or multiply or otherwise remain unspliced. Singly spliced and multiply spliced 
RNA which are then exported from the nucleus are called virion proteins. This is 
assisted by the Rev protein. Meanwhile, the unspliced RNA is translated into viral 
RNA by the host ribosomes which are also released into the cytoplasm. During this 
step, the new viral RNA and proteins are brought together and move towards the 
plasma membrane. These components are together known as immature virion when 
released from the host cell. Finally, the capsid is formed  
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Figure 1.1.2. HIV replication cycle. HIV replication cycle consists of 6 essential 
steps: 1) host cell binding and entry, 2) uncoating of the capsid, 3) reverse transcription 
of the viral RNA, 4) integration of the viral DNA complex into host DNA, 5) virus 
protein synthesis and assembly, 6) exocytosis or storage of viral RNA in the host cell. 
The virus matures and starts infecting uninfected cells. Figure retrieved from 
http://www.niaid.nih.gov/SiteCollectionImages/topics/hivaids/hivReplicationCycle.g
if. 
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by the P24 protein and the virus matures and becomes infectious to uninfected cells 
(Reitz & Gallo, 2010). 
A marked increase in immune activation of the host is a feature of HIV infection, 
including both innate and adaptive immunity. These two immune systems are 
important components to eradicate the virus once the host is infected. Innate immune 
response also known as natural immune response triggers the typical general immune 
events against many pathogens with no specificity of the particular invader. 
Conversely, an adaptive immune response specifically attacks the invader. CD4+ T 
cells are included in the adaptive immunity together with CD8+ T cells and B cells. 
HIV is capable of manipulating the host immune system to its advantage. For instance, 
infected CD4+ T cells will reach the lymph nodes, where activated T cells are located. 
Thus, the immune cells can be further infected resulting in depletion of CD4+ T cells 
(Swanstrom & Coffin, 2012; Maartens et al., 2014). 
The host cell has counteracting mechanisms to block the virus. Tetherin is a 
transmembrane protein of the host to inhibit the release of viral products. However, 
one of the viral proteins, Vpu, degrades tetherin to allow the release of viral particles. 
Another significant antiviral activity by the host is APOBEC-3G (apolipoprotein B 
mRNA editing enzyme, catalytic polypeptide-like 3G). APOBEC is an intracellular 
host defense mechanism against retroviruses which inhibits replication of the viruses. 
However, the Vif protein of HIV prevents incorporation of APOBEC into the virions.  
Vif functions by depleting cytoplasmic APOBEC thus promotes degradation of 
APOBEC3G via proteasomal pathway. Researchers had discovered new intracellular 
antiviral mechanism mediated by the tripartite motif (TRIM) family. The alpha 
isoform of TRIM (TRIM5α) is a retrovirus restriction factor that provides an early 
block to retrovirus infection. It binds to viral capsid hexamers and inhibits capsid 
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uncoating and reverse transcription. The mechanism of TRIM5α antiviral activity is 
not yet reported in details (Poli & Erfle, 2010). 
 
1.1.3. Development of vaccines and new HIV therapies 
In the absence of antiretroviral therapy, HIV infection will lead to the development of 
AIDS. The therapy is not a cure for the infection but delays the symptoms from 
worsening. To eradicate the virus, a protective vaccine is required. The development 
of a HIV vaccine has been very challenging. The most advanced vaccine to date is 
known as RV144. It has been tested up to phase III by a Thai group. They have tested 
a combination of two vaccines, ALVAC® HIV as the primary vaccine and AIDSVAX® 
B/E as the booster, which were based on the virus strains commonly found in Thailand. 
Haynes et al. (2012), mentioned that the tested vaccine protected some volunteers. The 
mechanism involved was the binding of immunoglobulin G antibodies to variable 1 
and 2 (V1/V2) regions of HIV-1 Env protein which resulted in non-functional Env 
protein.  
Several HIV-1 enzymes have been targeted for drug development such as integrase, 
reverse transcriptase (RT), and protease (PR) enzymes. Antiretroviral drugs have been 
developed since the introduction of zidovudine (AZT) at the National Cancer Institute 
in 1987. AZT is one of the nucleoside reverse transcriptase inhibitors (NRTIs) drugs 
besides retrovir. This group of drug inhibits reverse transcriptase activity during viral 
DNA production which acts as monotherapy to the patients. Another class of 
antiretroviral drugs is non-nucleoside reverse transcription inhibitors (NNRTIs) that 
also block the reverse transcription. The approved drugs in this class include 
nevirapine, delavirdine, and efavirenz. Then, protease inhibitors were introduced 
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namely ritonavir, saquinavir, and indinavir. HIV-1 protease plays a role in the viral 
gag and gag-pol polyprotein cleavage during virion maturation (Arts & Hazuda, 2012; 
Emamzadeh-Fard et al., 2013). These inhibitors were then used in combination with 
the RT inhibitors and are known as HAART. HAART has the ability to efficiently 
lower the viral activity and delay progression to AIDS despite its toxicity, side effects 
and antiviral drug resistance that follow after therapy (Arts & Hazuda, 2012). Integrase 
inhibitors are another class of antiretrovirals that block the formation of a 
preintegration complex of viral DNA and host DNA. Raltegravir is one of the approved 
integrase inhibitors introduced in 2007 followed by elvitegravir. Later, fusion or entry 
inhibitors were designed and approved clinically. Fuzeon, T20, and maraviroc are 
included in preventing fusion or entry of the HIV into the cells. The antiretroviral 
targets are depicted in Figure 1.1.3. 
Low adherence to HAART or extensive use of antiretroviral drugs among HIV-1 
patients is now a major challenge. The patients would slowly develop poor drug 
tolerability and cross-reactivity among the antiretroviral agents and other medications. 
This can lead to the evolution of drug resistance and consequently treatment failure. 
Due to this problem, there is always a pressing need for new HIV-1 treatments (Arts 
& Hazuda, 2012; Paydary et al., 2013).  
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Figure 1.1.3. HIV life cycle and antiretroviral targets. Image above shows the sites 
of action of different classes of antiretroviral drugs (Maartens et al., 2014). 
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The discovery of antibodies against HIV-1 has increased progressively due to a better 
understanding of viral structures and mechanism of infection. This is especially against 
the HIV-1 Env protein which could prevent viral entry. With increasing knowledge on 
the glycoproteins, many more neutralizing antibodies (NAbs) were able to be 
developed (Ringe & Bhattacharya, 2013) such as the first broadly neutralizing human 
monoclonal antibody (mAb) b12. This mAb was found to neutralize clade B viral 
isolates at the rate of 50%. The Ab targets the CD4 binding site of gp120. It was 
reported in 1994 that b12 was selected by phage display library method from the bone 
marrow of HIV-1 infected patient (Barbas & Barbas, 1994). In 1992, mAbs against the 
P24 protein were produced from hybridomas by Konovalov and group (Konovalov et 
al., 1992). Their binding activities were examined and the antigenic epitopes of p24 
were determined. However, these antibodies were only used to study the antigenic 
properties of the P24 protein.  
HIV-1 CA protein structure consists of two independently folded domains, C-terminus 
and N-terminus domains, which are connected by a flexible linker (Sticht et al., 2005; 
Thenin-Houssier & Valente, 2016). The CA protein structure is depicted in Figure 
1.1.4. Tang et al. (2003) reported that viral particles with unstable capsid due to 
mutations would severely reduce infectivity. They discovered a potent molecule 
inhibitor of HIV-1 CA, called CAP-1 (Tang et al., 2003; Kelly et al., 2007; Adamson 
et al., 2009). This compound was found to inhibit capsid assembly during the 
maturation step which resulted in impaired virus production.  
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Figure 1.1.4. Organization and structure of HIV-1 Gag and CA proteins. The left 
panel shows a schematic secondary structure of HIV-1 Gag polyprotein. Individual 
domains are represented in different colors. Protease cleavage sites are indicated by 
the arrowheads. The right panel shows an illustrative representation of the HIV-1 
capsid structure with highlighted ligand binding sites (Machara et al., 2015; Thenin-
Houssier & Valente, 2016). 
MA (matrix), CA (capsid), NC (nucleocapsid), SP (spacer peptides), and p6 (protein 
of 6 kDa). 
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However, it was found not affecting the stability of pre-assembled CA-NC 
(nucleocapsid) complex in vitro (Fricke et al., 2013). More recent publications 
reported the details of specific inhibitors of HIV CA assembly by binding to the C-
terminal domain (CTD) (Sticht et al., 2005; Bocanegra et al., 2011; Zhang et al., 2011; 
Marchara et al., 2015; Thenin-Houssier et al., 2016) and N-terminal domain (NTD) 
(Kortagere et al., 2012; Lemke et al., 2012; Kortagere et al., 2014) of the CA protein. 
A capsid assembly inhibitor (CAI) was reported to bind the CA-NTD and acted at the 
late stage of the HIV-1 life cycle (Sticht et al., 2005). However, due to its low cell 
permeability, it was not suitable for blocking HIV-1 replication in cells. Several years 
after that, a modified peptide was designed based on the CAI peptide to overcome its 
limitation. Zhang et al. (2008) successfully produced a cell-penetrating peptide known 
as NYAD-1 by using hydrocarbon stapling technique. This technique stabilized the 
peptide to penetrate the cells, but the compound has drawbacks of poor inhibitory 
effect and short half-life. PF74 is another CA inhibitor that displayed inhibitory 
activities at the early and late stages of virus life cycle, and can bind to both CA-NTD 
and -CTD (Blair et al., 2010). Then, a PF74-resistant mutant virus that alters the 
interaction with the host factors required for viral entry was developed (Zhou et al., 
2015). Machara et al. (2015) identified a CA-CTD specific inhibitor, 2-
arylquinazolines, which is capable of blocking viral replication. However, it was doubt 
to have rapid clearance in the cells which thus makes it inefficient. The most recent 
CA inhibitor is Ebselen (Thenin-Houssier et al., 2016). It was shown to covalently 
bind to the CA-CTD and inhibit dimerization of the CA at the early stage of HIV-1 
life cycle, by impairing the uncoating events. However, it was reported to have low 
specificity.  
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The above-mentioned studies had shown that the HIV-1 CA protein is an attractive 
target for drug development. However, there is still a pressing need to continue the 
search of therapeutic molecules against the HIV-1 which are more stable, less-
resistant, and able to intracellularly inhibit viral infection.   
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1.1.4. Antibody Molecule 
Antibodies are produced in response to infections and foreign bodies. They are also 
known as immunoglobulin (Ig) which is the folding of the amino acid residues in a 
globular motif. Ig is attached to foreign substances called antigens, to be destroyed by 
the immune system. Antibodies are synthesized by B cells in two forms, membrane-
bound antibodies, and secreted antibodies. This large molecule with molecular weight 
of ~150 kDa comprises two identical units of heavy- and light-chains which are 
produced by rearranged germline variable (V), diversity (D) and joining (J) gene 
segments at the heavy chain locus while V and J gene segments at the light chain locus 
(Liao et al., 2009). Figure 1.1.5 shows different antibody structures that are composed 
of heavy and light chains covalently linked by disulfide bonds. The heavy chain 
consists of one V region and three or four C (constant) regions. The light chain is 
composed of one V region and one C region. The V region of heavy chain (VH) and 
the adjoining V region of the light chain (VL) form the antigen binding domain 
(Janeway et al., 2001; Hudson & Souriau, 2003; Lo et al., 2008).  
There are five classes of antibodies that differ in their heavy-chain, termed as IgG, 
IgM, IgA, IgD, and IgE. Most of them are distributed or transported to the 
compartments of the body with appropriate effector functions for each antibody class 
which are determined by their isotypes (Elgert, 1998; Janeway et al., 2001; Abbas et 
al., 2015).  
IgG contains gamma (ɣ) chain in the heavy chain region and is the most abundant Ig 
present in serum. IgG subclasses are including IgG1, IgG2, IgG3, and IgG4. It 
responds directly to toxins and viruses. In HIV, it was reported that IgG3 antibodies 
are more effective in neutralizing the virus than IgG1 antibodies. IgG is the only  
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Figure 1.1.5. Schematic representations of the antibody structure. (a) Domain 
organization of IgG. Antigen binding area is composed of variable heavy (VH) and 
light (VL) chains. Constant domains CH2 and CH3 function as the effector component 
of the antibody for receptor binding. (b) The dimeric secretory IgA (SIgA) and 
pentameric IgM structures. SIgA is a dimer in which monomers are disulfide-linked 
via J-chain. IgM monomer with a pair of Cµ2 domains replacing the hinge, unpaired 
Cµ3 domains, and C-terminal tailpieces (Little et al., 2000). 
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antibody type that is capable of crossing the placenta and is also involved in secondary 
immune response. 
IgM normally exists as a pentamer which contains mu (µ) chain as the heavy chain. It 
is the first type of antibody expressed on the surface of B cells during an immune 
response. It provides early fight against pathogens. Its pentameric structure is essential 
for effective activation of the complement system (Abbas et al., 2015). 
IgD is composed of delta (δ) chain in the heavy chain region. It works with IgM in the 
B cell development (Abbas et al., 2015). However, it circulates at very low levels in 
the serum with a short serum half-life.  
IgE is a monomer type antibody with epsilon (ε) chain. It binds to allergens and is 
associated with hypersensitivity reactions as well as protects against parasitic worms 
(Abbas et al., 2015).  
IgA is a highly produced Ig that can be found at mucosal surfaces like the gut, 
respiratory and urogenital tracts. It protects against toxins, virus, and bacteria by 
neutralization or prevention of binding to the mucosal surface (Abbas et al., 2015). It 
can also be found in secretions of breast milk as the ‘first milk’ given to the neonate 
by the mother.   
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1.1.5. Generation of scFv antibodies 
The high molecular weight of immunoglobulins (Ig) limit not only their use in high 
throughput of biochemical and structural studies but also less efficient as biological 
therapy (Farajnia et al., 2014). There are various types of recombinant antibody 
formats that have been engineered over the last two decades. Being the most popular 
one, scFv consists of antibody variable domains connected by a flexible linker and is 
the mostly used to overcome this drawback (Wӧrn & Plückthun, 2001).  
 ScFv is described as a single-chain antibody fragment, a smaller version of the 
antibody with the complete antibody antigen-binding site. The smallest Ig fragment 
containing the antigen-binding site is the Fv fragment. It consists of the variable heavy 
(VH) and –light (VL) chains. The linker between Fv holds higher stability than the Fv 
itself. It is then recognized as a single-chain Fv (scFv). The length of linker would 
determine the formation of multimeric forms of the scFv (Figure 1.1.6). Linkers can 
be incorporated in either VL – linker – VH or VH – linker – VL orientation. Usually, the 
linker is composed of 15 amino acids with (Gly4Ser)3. In order to produce scFv, 
enzymatic cleavage can be done but it is considerably a difficult and less stable 
process.  
ScFvs can be constructed by amplifying the variable regions from mRNA of 
hybridoma cells using PCR (Toleikis et al., 2004). ScFvs can be produced in E. coli 
using different types of promoters; phage λ, LAC, TAC, or phage T7 (Bird and Walker, 
1991). However, there were reports that scFv proteins were usually insoluble in E. coli 
(Sodoyer, 2004), thus they require solubilization and refolding steps. This would be 
time consuming and laborious. Even with these problems, there were reports of 
successful scFv expressions  
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Figure 1.1.6. Recombinant antibody constructs. (a) Monovalent fragments of the 
antibody molecule capable of binding antigen. Fab, Fv, and disulphide-stabilized Fv 
(dsFv) fragments consist of two separate chains while scFv and single VH fragments 
are composed of a single polypeptide. (b) ScFv with a peptide linker that connects VH 
and VL domains, or fused directly without a linker. Different structure formations exist 
with different length of the linker. Shorten linker may develop a diabody (scFv dimer), 
triabody (trimer), and tetrabody (tetramer) (Little et al., 2000). 
Ag (antigen) and L (linker). 
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of soluble scFv in Bacillus subtilis which did not require the refolding step (Bird and 
Walker, 1991).  
ScFv has become the first option for therapeutic purposes nowadays for having lower 
retention time in nontarget tissues than Fab. In addition, scFv has more rapid blood 
clearance and better tumor penetration due to its small size (Bird and Walker, 1991; 
Kipriyanov et al., 1997; Little et al., 2000; Chadd & Chamow, 2001; Hagemeyer et al., 
2009; Farajnia et al., 2014). A previous experiment showed that the use of scFv was 
better than the larger antibody (Fab) (Bird et al., 1988). There was a study of scFv and 
Fab being injected into tumor-bearing mice. It was observed that clearance of the scFv 
was 7 times faster than the Fab molecules. This demonstrated that scFv reaches the 
tissues and organs faster than the Fab. It could target and localize the tumor tissue 
better than the Fab (Bird et al. 1988).  
Besides, some properties can be easily tailored such as antigen-binding affinity, 
stability, and expression level of the antibody fragment as compared to the full-length 
Ig (Mazor et al., 2007). It has become a promising alternative to monoclonal antibodies 
(Farajnia et al., 2014; Yan et al., 2014). ScFv provides many other applications. Apart 
from being used as in vivo diagnosis and treatment of diseases, it can be used in 
biomarker validation (Baird et al., 2010), in vitro diagnosis, biosensors, catalytic 
antibodies and can be genetically engineered to enhance its functions.  
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1.1.6. Phage display technology 
Phage display is a highly powerful technology for producing a large amount of 
peptides, proteins, and antibodies with novel selection methods to screen the 
polypeptides with novel functions. This technology applies the physical linkage 
between phenotype and genotype of the polypeptides that are fused to the 
bacteriophage coat proteins (Fagerlund et al., 2008; Bazan et al., 2012). The phenotype 
of the protein is displayed by the bacteriophage while the genotype encoding that 
molecule is packaged within the same virion (Figure 1.1.7). This criterion allows the 
selection and amplification of specific clones with the desired binding specificity from 
diverse phage clones. In addition, this technique allows easy determination of the 
specific binder through DNA sequencing. It was first introduced by George Smith in 
1985 and has become an effective tool with applications in the discovery of ligands 
for affinity chromatography and drugs, in the study of protein/protein interactions, and 
in epitope mapping (Ehrlich et al., 2000; Fagerlund et al., 2008) thus allowing 
development of new drugs, vaccines, genetic mapping, and biosensing (Qi et al., 
2012).  
 
 
 
 
 
 
 
